Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating foot pain disease including botulinum toxin and hyaluronic acid, and foot pain disease treatment method using same

A technology of botulinum toxin, hyaluronic acid, applied in the field of treating foot pain diseases

Pending Publication Date: 2020-03-24
ATGC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Botox may cause side effects such as headaches, ptosis, difficulty swallowing and xerostomia, but Botox does not directly cause death and it is known that Botox in the proper doses does not create security issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating foot pain disease including botulinum toxin and hyaluronic acid, and foot pain disease treatment method using same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Embodiment 1. Experimental preparation and experimental method

[0056] 1-1. Production of experimental materials

[0057] Hyaluronic acid (HA) was dissolved in 50 mM sodium phosphate buffer (pH 6.8) to obtain a concentration of 10 mg / ml. After measuring the body weight of the animals on the day of administration, put botulinum toxin type A (BoNT / A) into the prepared hyaluronic acid respectively according to the average body weight of the test group, so that botulinum toxin type A (BoNT / A) The final doses of 1.5 U / kg and 3.0 U / kg were obtained, and the resulting mixture was stirred and mixed for 30 minutes.

[0058] 1-2. Animal model

[0059] For the animal model of this experiment, 100 μl (1 mg / mL) of Freund's complete adjuvant (FCA) was administered to the right hind paw of Sprague-Dawley (SD) rats by subcutaneous injection to induce the model. For group construction, a total of 5 groups were generated: blank sham group ( sham), in which the model was not induced...

Embodiment 2

[0064] Example 2. Confirm the effect of botulinum toxin and hyaluronic acid compound preparation on inhibiting foot pain in the foot hyperalgesia model induced by FCA

[0065]FCA is a material that induces pain by causing an inflammatory response when applied subcutaneously to the sole of the hind paw, which has been widely used to study pain and evaluate efficacy in FCA-induced animal models, and is particularly suitable for use in The sole causes inflammation to assess the extent of foot pain conditions such as plantar fasciitis. Therefore, in order to confirm the effect of HA+BoNT / A on the treatment of foot pain using the FCA-induced model, the von Frey test was tested by the method in Example 1 as a parameter for measuring pain.

[0066] 2-1 Von Frey Test

[0067] To assess the degree of confirmation and degree of model induction after administration of FCA, a Von Frey test was carried out by the method in Examples 1-3, in this case the higher the value on the graph, the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pharmaceutical composition which is for treating foot pain diseases and includes botulinum toxin and hyaluronic acid, and a foot pain disease treatment method usingsame. More specifically, the composition according to the present invention can exhibit a synergistic action of increasing both anti-inflammatory and anti-pain activity through an inflammation-inhibiting effect on foot pain diseases such as pain arising from plantar fasciitis, foot fasciitis, Achilles tendon damage, flat feet, diabetes, and gout. Thus, the composition according to the present invention is expected to be able to be usefully used subcutaneously in the foot as a liquid injection agent that exhibits an effect of treating or improving foot pain diseases.

Description

technical field [0001] The present invention relates to a pharmaceutical composition comprising botulinum toxin and hyaluronic acid for treating foot pain diseases, and a method for using the pharmaceutical composition to treat foot pain diseases. Background technique [0002] Botulinum toxin is a neurotoxin produced by the Gram-positive anaerobic bacterium Clostridium botulinum. Botulinum toxin is divided into eight neurotoxins, seven of which (A, B, C, D, E, F, and G) may cause nerve paralysis. Among them, the deadliest botulinum toxin, known as a natural biological agent, is type A. The toxin protein is 150 kDa in size and forms a complex with non-toxin proteins. The size of the complex depends on the type of neurotoxin, many up to 900kDa. [0003] Botulinum toxin has an effect of causing temporary muscle paralysis, and causes partial muscle paralysis by a mechanism of inhibiting the secretion of acetylcholine at the neuromuscular junction of motor nerve endings (incorp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/728A61K38/48A61K9/08A61P29/00A61P3/10A61P19/06
CPCA61K31/728A61P29/00A61K9/0019A61K47/36A61K47/02A61K38/4893A61K2300/00A61K9/08A61P3/10A61P19/06A61K35/66
Inventor 张成洙李学燮安用植金钟孝申胜镇
Owner ATGC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com